-
CD39: A Novel Target to Overcome Immunosuppression in Cancer(Post)
Introduction to CD39 and Cancer Immunosuppression CD39 is an ectonucleotidase enzyme that plays a crucial role in generating adenosine, a powerful immunosuppressive molecule within the tu
Unlocking the Potential of Anti-CD47 in Cancer Immunotherapy(Post)Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha
B7-H3: A Promising New Target in Tumor Immunotherapy(Post)B7-H3, also known as CD276, is a member of the B7 family of immune checkpoint molecules that has emerged as a compelling target in tumor immunotherapy. Initially recognized for its role i
Rosopatamab: Unveiling the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About RosopatamabWhat is Rosopatamab?Rosopatamab is a monoclonal antibody targeting CD47, a critical immune checkpoint that helps cancer cells evade immune detection. By bloc
Turning Tumors Against Themselves: In Vivo Reprogramming of Cancer Cells into Dendritic Sentinels(Post)Imagine a future where cancer cells, once masters of disguise, are forced to reveal themselves and even train the body's immune system to fight back. This isn't science fiction; it's the groundbreaki
Physiological Roles for IL-33 | Assay Genie(Post)By Charlotte O'Donnell PhD A role for IL-33 in Barrier Function and Epithelial Wound Healing
Unconventional T Cells: Already Armed, and No MHC Required(Post)Most immunology is written as though a T cell must first be told what to look for. Three lineages did not read that memo. γδ T cells, invariant NKT cells and MAIT cells leave the thymus with their ef
Microtubule and Mitosis review(Post)Introduction Microtubules are key components of the cytoskeleton and are composed of alpha and beta tubulin. These dimerise in a head to tail fashion to form 13 linear protofilaments.
Biosimilar: Expanding Access to Monoclonal Antibody-Based Therapies(Post)1. What is a Biosimilar? A biosimilar is a biologic medical product that is highly similar to an already-approved reference biologic. While minor differences in clinically inactive compon
Wnt Signalling Pathway in Immunity(Post)What is Wnt Signalling? The Wnt signalling pathway is an evolutionarily conserved pathway that plays critical roles in the regulation of determining cell fate, polari
Guselkumab: Advancing Psoriasis and Autoimmune Disease Research Through IL-23 Targeting(Post)Quick Facts About GuselkumabWhat is Guselkumab?Guselkumab is a biologic therapy that selectively targets the p19 subunit of interleukin-23 (IL-23), playing a critical role in inflammator
Pathological functions of IL-33/ST2 in IBD and Cancer(Post)By Charlotte O'Donnell PhD < As IL-33/ST2 is such a potent inducer of inflammation, it is not surprising that dysr
Galegenimab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eli
Immunohistochemical Staining, Antibodies & Buffers(Page) Trauma Immunology(Post)Traumatic injuries & death When I ask people what the leading cause of death is in the United States in people age 44 and under, they generally reply saying
Agarose vs Polyacrylamide: A Comparative Analysis(Post)Techniques · Gel ElectrophoresisAgarose vs Polyacrylamide: A Comparative AnalysisAgarose and polyacrylamide are the two workhorse gel matrices of electrophoresis. Agarose gels resolve larger DNA and R
Ipilimumab and Nivolumab: Advancing Research on CTLA-4 in Cancer Therapy(Post)What You Need to Know About IpilimumabWhat is Ipilimumab?Ipilimumab is a monoclonal antibody that targets CTLA-4, a protein involved in downregulating the immune system, to boost the bod
Brodalumab: A Breakthrough in IL-17 Receptor Blockade for Psoriasis and Beyond(Post)Quick Facts About BrodalumabWhat is Brodalumab?Brodalumab is a monoclonal antibody that targets the IL-17 receptor to treat immune-mediated conditions like moderate-to-severe plaque psor
Rescuing Exhausted T Cells: A New Frontier in Cancer Immunotherapy(Post)For decades, the fight against cancer has been a story of incremental gains. But what if we could fundamentally shift the battlefield, turning the body's own immune system into a precision-guided weap
Fc Receptors Explained: ADCC, ADCP, CDC and the CD32B Brake(Post)An antibody's variable domains decide what it binds. Its Fc decides what happens next — and that is not a detail of formulation, it is half the mechanism. Which Fcγ receptor the constant region engag